⏳ Fetching live dividend data...
Home › Calculator › APGN Dividend Calculator 2026
Apexigen, Inc. · NASDAQ
Price: $0.39 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in APGN → $830482.98M in 10 years · $58,032,715,801.07/month
Apexigen Inc., established in 2010 and based in San Carlos, California, is a clinical-stage biotechnology company dedicated to the discovery and advancement of antibody-based therapies for oncological diseases. The company's developmental pipeline features several promising candidates. A primary focus is APX005M, a humanized agonist antibody currently in Phase II clinical trials. This therapeutic agent is being explored for its efficacy against a variety of solid tumors, including melanoma, esophageal and gastroesophageal junction cancers, sarcoma, and rectal and ovarian malignancies, often in conjunction with other established treatments like immunotherapy, chemotherapy, radiation therapy, and cancer vaccines. Additionally, Apexigen is progressing APX601, a humanized antagonist antibody, through Phase I/II clinical trials for numerous tumor indications. Rounding out their experimental portfolio is APX801, an NK cell engager engineered to stimulate natural killer cells to eradicate cancerous cells.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open APGN position with:
Real after-tax yield depends on where you live and how you hold APGN.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 519.35% | 516.55% | $51,935 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 441.45% | 438.65% | $44,145 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 415.48% | 412.68% | $41,548 / yr |
| 🇬🇧 UK ISA | 0% | 519.35% | 516.55% | $51,935 / yr |
| 🇬🇧 UK Taxable | 8.75% | 473.91% | 471.11% | $47,391 / yr |
| 🇨🇦 TFSA | 0% | 519.35% | 516.55% | $51,935 / yr |
| 🇨🇦 CA Taxable | 25% | 389.51% | 386.71% | $38,951 / yr |
| 🇦🇺 Super (pension) | 15% | 441.45% | 438.65% | $44,145 / yr |
| 🇦🇺 AU Taxable | 30% | 363.55% | 360.75% | $36,355 / yr |
| 🇩🇪 DE Taxable | 26.375% | 382.37% | 379.57% | $38,237 / yr |
| 🇫🇷 FR Taxable | 30% | 363.55% | 360.75% | $36,355 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
APGN pays quarterly — 4 times per year. Next ex-div: TBD.
How APGN compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for APGN sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| D-Return | 2023-08-23 | 100,000 | $2.65 | $265.0K | ||
| D-Return | 2023-08-23 | 1,845 | $1.75 | $3.2K | ||
| D-Return | 2023-08-23 | 146,383 | — | — | ||
| D-Return | 2023-08-23 | 100,000 | $2.65 | $265.0K | ||
| D-Return | 2023-08-23 | 12,383 | $11.50 | $142.4K | ||
| D-Return | 2023-08-23 | 34,084 | $6.94 | $236.5K | ||
| D-Return | 2023-08-23 | 100,000 | $2.65 | $265.0K | ||
| D-Return | 2023-08-23 | 5,000 | $11.50 | $57.5K | ||
| D-Return | 2023-08-23 | 100,000 | $2.65 | $265.0K | ||
| D-Return | 2023-08-23 | 10,000 | — | — |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the APGN dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Apexigen, Inc. (APGN) is currently trading at $0.39, trading near its 52-week low. The current dividend yield is 519.35% based on an annual payout of $2.00 per share.
Apexigen, Inc. (APGN) is a healthcare stock currently trading at $0.39 with a dividend yield of 519.35%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
⏱️ Takes 30 seconds · No signup · Free forever